Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas

Cancer Treatment Reviews

Volumn 36, Issue SUPPL. 3, 2010, Pages

  Fazio, Nicola ^a   Cinieri, Saverio ^a,b   Lorizzo, Katia ^a   Squadroni, Michela ^a   Orlando, Laura ^a,b   Spada, Francesca ^a   Maiello, Evaristo ^c   Bodei, Lisa ^a   Paganelli, Giovanni ^a   Delle Fave, Gianfranco ^d   De Braud, Filippo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Oncologia Medica ^*  (Italy)

^c S Giovanni Rotondo (Foggia)   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

NEC; Targeted therapy

Indexed keywords

ANGIOPEPTIN; AUTOGEL; BEVACIZUMAB; CAPECITABINE; COLESTYRAMINE; DOPAMINE 2 RECEPTOR; EVEROLIMUS; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; LAR; LOPERAMIDE; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; OXALIPLATIN; PASIREOTIDE; PEGINTERFERON; PEGINTERFERON ALPHA2B; PENTETATE INDIUM IN 111; PLACEBO; RADIOISOTOPE; SOMATOSTATIN RECEPTOR; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CARCINOID SYNDROME; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENTEROPANCREATIC NEUROENDOCRINE CARCINOMA; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREAS CARCINOMA; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; RASH;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NEUROENDOCRINE; HUMANS; INDOLES; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; PYRROLES; RECEPTORS, SOMATOSTATIN; SIROLIMUS; SOMATOSTATIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78649754940     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/S0305-7372(10)70026-8     Document Type: Article

References (112)

1. Modlin IM, Lye KD, Kidd M A 5-decade analysis of 13715 carcinoid tumors. Cancer 2003, 97:934-959.
2. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008, 9:61-72.
3. Yao JC, Hassan M, Phan A, et al. One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26:3063-3072.
4. Kaltsas GA, Besser GM, Grossman AB The diagnosis and medical management of advanced endocrine tumors. Endocr Rev 2004, 25:458-511.
5. Solcia E, Kloppel G, Sobin LH Histological Typing of Endocrine Tumours 2000, Springer, Berlin. 2nd edn.
6. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006, 449:395-401.
7. Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007, 451:757-762.
8. Steinmuller T, Kianmanesh R, Falconi M, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008, 87:47-62.
9. Mitry E, Rougier The treatment of undifferentiated neuroendocrine tumors. Critical Rev Oncol Hematol 2001, 37:47-51.
10. Pape UF, Berndt U, Mueller-Nordhorn J, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008, 15:10-83-10-97.
11. Patel YC Somatostatin and its receptor family. Front Neuroendocrinol 1999, 20:157-198.
12. Patel YC Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997, 20:348-367.
13. Patel YC, Srikant CB Somatostatin receptors. Trends Endocrinol Metab 1997, 8:398-405.
14. Pawlikowski M The incidence of somatostatin receptors in human neoplasms in the light of ex vivo-in vitro studies. Pol J Endocrinol 2006, 57:238-243.
15. Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994, 93:1321-1325.
16. Panetta R, Patel YC Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 1995, 56:333-342.
17. De Herder WW, Hofland LJ, van der Lely AJ, Lamberts SWJ Somatostatin receptors in gastroenteropancreatic neuroendocrine tumours. End Rel Cancer 2003, 10:451-458.
18. Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002, 440:461-475.
19. Pisarek H, Pawlikowski M, Kunert-Radek J, Kubiak R, Winczyk K SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors. Folia Hyst Cytol 2010, 48:142-147.
20. Kulaksis H, Eissele R, Rossler D, et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with specific antibodies. Gut 2002, 50:52-60.
21. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993, 20:716-731.
22. 111In-Pentetreotide scintography in the detection of insulinomas: importance of SPECT imaging. J Nucl Med 2000, 41:459-462.
23. Averous J, Proud CG When translation meets transformation: the mTOR story. Oncogene 2006, 25:6423-6435.
24. Easton JB, Houghton PJ mTOR and cancer therapy. Oncogene 2006, 25:6436-6446.
25. Land SC, Tee AR Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007, 282:20534-20543.
26. Mita MM, Mita A, Rowinsky EK The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003, 4(Suppl 1):S169-S177.
27. Francalanci P, Diomedi-Camassei F, Purificato C, et al. Malignant pancreatic endocrine tumor in a child with tuberous sclerosis. Am J Surg Pathol 2003, 27:1386-1389.
28. Wang L, Ignat A, Axiotis CA Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol 2002, 10:139-146.
29. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 2005, 102:8573-8578.
30. Blansfield JA, Choyke L, Morita SY, et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 2007, 142:814-818.
31. Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010, 28:245-255.
32. Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998, 32:133-138.
33. La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 2003, 34:18-27.
34. Hopfner M, Baradari V, Huether A, Schofl C, Scherubl H The insulinlike growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocrine Relat Cancer 2006, 13:135-149.
35. Chaudhry A, Funa K, Oberg K Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol 1993, 32:107-114.
36. Chaudhry A, Oberg K, Gobl A, Heldin CH, Funa K Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Res 1994, 14:2085-2091.
37. Christofori G, Naik P, Hanahan D Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995, 9:1760-1770.
38. Nilsson O, Wängberg B, Theodorsson E, Skottner A, Ahlman H Presence of IGF-I in human midgut carcinoid tumours - an autocrine regulator of carcinoid tumour growth?. Int J Cancer 1992, 51:195-203.
39. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP, Caplin ME Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol 2006, 18:355-360.
40. Funa K, Papanicolaou V, Juhlin C, et al. Expression of platelet derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. Cancer Res 1990, 50:748-753.
41. Lopez T, Hanahan D Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2002, 1:339-353.
42. Rubbia-Brandt L, Terris B, Giostra E, Dousset B, Morel P, Pepper MS Lymphatic vessel density and vascular endothelial growth factor-C expression correlate with malignant behavior in human pancreatic endocrine tumors. Clin Cancer Res 2004, 10:6919-6928.
43. Zhang J, Jia Z, Li Q, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007, 109:1478-1486.
44. Hopfner M, Schuppan D, Scherubl H Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor recpetors and their signaling pathways: recent advances and future perspectives. World J Gastroenterol 2008, 14:2461-2473.
45. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ Octreotide. N Engl J Med 1996, 334:246-254.
46. Fazio N, de Braud F, Delle Fave G, Oberg K Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination. Ann Oncol 2007, 18:13-19.
47. Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: pharmaco-kinetics, pharmacodynamics, efficacy and tolerability in acromegalic patients. Metabolism 1995, 44:18-26.
48. Caron P Somatuline® Autogel ®, a new formulation of lanreotide for the treatment of acromegalic patients. Ann Endocrinol 2002, 63(2 pt3):2S19. S24.
49. Gorden PH, Comi RJ, Maton PN, Go WLW Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989, 110:35-50.
50. Arnold R, Simon B, Wield M Treatment of neuroendocrine GEP tumours with somatostatin analogues. Digestion 2000, 62(Suppl 1):84-91.
51. Lamberts SWJ, Krenning EP, Reubi JC The role of somatostatin and its analogs in the diagnosis and treatments of tumors. Endocrinol Rev 1991, 12:450-482.
52. Thompson JS Epidermal growth factor inhibits somatostatin-induced apoptosis. J Surg Res 1999, 81:95-100.
53. Liu D, Martino G, Thangaraju M, et al. Caspase-8-mediated intracellular acidification precedes mitochondrial dysfunction in somatostatin-induced apoptosis. J Biol Chem 2000, 275:9244-9250.
54. Lahlou H, Guillermet J, Hortala M, et al. Molecular signalling of somatostatin receptors. Ann NY Acad Sci 2004, 1014:121-131.
55. Furukawa M, Raffeld M, mateo C, et al. Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clin Cancer Res 2005, 11:3233-3242.
56. Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanism. End Relat Cancer 2008, 15:701-720.
57. Saltz L, Trochanowsky G, Buckley M, et al. Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumours. Cancer 1993, 72:244-248.
58. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumors. Gut 1996, 38:430-438.
59. Di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer 1996, 77:402-408.
60. Aparicio T, Ducreaux M, Baudin E, et al. Antitumor activity of somatostatin analogues in progressive metastatic neuroendocrine tumors. Eur J Cancer 2001, 37:1014-1019.
61. Strosberg J, Gardner L, Kvols L Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 2009, 89:471-476.
62. Study of lanreotide autogel in non-functioning entero-pancreaticendocrine tumours Identifier:NCT00353496. http://www.clinicaltrial.gov/.
63. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrinemidgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009, 27:4656-4663.
64. Hofland LJ, Lamberts SW The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003, 24:28-47.
65. Harris A, Redfern JS Octreotide treatment of carcinoid syndrome: analysis of published dose/titration data. Aliment Pharmacol Ther 1998, 9:387-394.
66. Eriksson B, Renstrup J, Imam H, Oberg K High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumours: clinical and biological effects. Ann Oncol 1997, 8:1041-1044.
67. Anthony L, Johnson D, Hande K, et al. Somatostatin analogue phase 1 trials in neuroendocrine neoplasms. Acta Oncol 1993, 32:217-223.
68. Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002, 146:707-716.
69. Schmid HA Pasireotide (SOM230): Development, mechanism of action and potential applications. Mol Cell Endocrinol 2008, 14:69-74.
70. Wolin EM, Kvols LK, Ezzat S, et al. Pasireotide LAR in patients with metastatic carcinoid tumors: Pharmacokinetics (PK) and safety results from a randomized, multicenter, phase I study. ASCO GI 2009, Abstr. 93.
71. Kvols BW, Oberg K, Glusman JE, et al. The SOM230 Carcinoid Study Group. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study. J Clin Oncol 2006, ASCO Annual Meeting Proceedings Part I 2006, 24(18S). Abstr. 4082.
72. Safety and efficacy of pasireotide long acting release vs. octreotide long acting release in patients with metastatic carcinoid disease Identifier: NCT00690430. http://www.clinicaltrial.gov/.
73. O'Toole D, Saveanu A, Couvelard A, et al. The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol 2006, 155:849-857.
74. Kwekkeboom DJ, Bakker WH, Kooij PP, et al. [177Lu-DOTAO Tyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001, 28:1319-1325.
75. Krenning EP, Valkema R, de Herder W, et al. Peptide receptor radionuclide therapy of gastroenteropancreatic neuroendocrine tumors. A Century of Advances in Neuroendocrine Tumor Biology and Treatment 2007, 434-443. Felsenstein CCCP, Hannover, Germany. I. Modlin, K. Oberg (Eds.).
76. Waldherr C, Pless M, Maecke HR, et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001, 12:941-945.
77. Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003, 30:207-216.
78. Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006, 36:147-156.
79. Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008, 35(10):1847-1856.
80. Bodei L, Ferone D, Grana C, et al. Peptide receptor therapies in neuroendocrine tumours. J Endocrinol Invest 2009, 32(4):360-369.
81. Kwekkeboom DJ, van de Herder W, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] Octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008, 26:2124-2130.
82. van Essen M, Krenning EP, Kam B, et al. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008, 35:743-748.
83. Kwekkeboom DJ, de Herder WW, van Eijck CHJ, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010, 40:78-88.
84. Bodei L, et al. PRRT in entero-pancreatic NETs: a multidisciplinary approach at the European Institute of Oncology. IEO NET Study Group, ENETS 2008, poster session.
85. Zitzmann K, De Toni EN, Brand S, et al. The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007, 85:54-60.
86. Hörsch D, Tielke S, Schrader J Expression and activation of mTOR in neuroendocrine tumors. Effects of mTOR inhibition by RAD001 upon growth, cell cycle regulation and signalling in neuroendocrine cell lines. J Clin Oncol 2007, 25(18S):10570.
87. Von Wichert G, Jehle PM, Hoeflich A, et al. Insulin-like growth factor-1 is an autocrine regulator of chromogranina A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000, 60:4573-4581.
88. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66(3):1500-1508.
89. Charland S, Boucher MJ, Houde M, Rivard N Somatostatin inhibits Akt phosphorylation and cell-cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral-pancreatic acinar cells. Endocrinology 2001, 142:121-128.
90. Pokrajac A, Frystyk J, Flyvbjerg A, Trainer PJ Pituitary-independent effect of octreotide on IGF1 generation. Eur J Endocrinol 2009, 160:543-548.
91. Yao JC, Phan A, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate grade neuroendocrine tumours: results of a phase II study. J Clin Oncol 2008, 26:4311-4318.
92. Yao JC, Lombard-Bohas C, Baudin E, et al. A phase II trial of daily oral RAD001 (everolimus) in patients with metastatic pancreatic neuroendocrine tumors (NET) after failure of cytotoxic chemotherapy. J Clin Oncol 2010, 28:69-76.
93. Kulke M, Blaszkowsky LS, Zhu AX, et al. Phase I/II study of everolimus (RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET). ASCO GI Symposium 2010; Abstr. 223.
94. Chan JS, Ryan DP, Fuchs C, al. Phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET). ASCO GI Symposium 2010; Abstr. 238.
95. Identifier: NCT00412061. http://www.clinicaltrial.gov/.
96. Chan JA, Mayer RJ, Jackson N, Malinowski P, Regan E, Kulke M Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors (NET). J Clin Oncol 2010, 28(Suppl). Abstr. e14597.
97. Iida S, Miki Y, Ono K, et al. Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors. ENETS 2010, Abst B12.
98. Yao JC, Phan AT, Fogleman D, et al. Randomized run-in study of beva-cizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol 2010, 28(Suppl):15s. [abstract 4002].
99. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet derived growth factor receptors: determination of pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
100. Faivre S, Demetri G, Sargent W, Raymond E Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007, 6:734-745.
101. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patient with cancer. J Clin Oncol 2006, 24:25-35.
102. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26:3403-3410.
103. Niccoli P, Raoul J, Bang Y, et al. Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET). J Clin Oncol 2010, 28(Suppl):15s. [abstract 4000].
104. Vinik A, Bang Y, Raoul J, et al. Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial. J Clin Oncol 2010, 28(Suppl):15s. [abstract 4003].
105. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008, 26:1316-1323.
106. Identifier: NCT00569127. http://www.clinicaltrial.gov.
107. Kulke MH, Stuart K, Earle CC, et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2006, 24(18 Suppl):4044S.
108. Kunz PL, Kuo T, Zahn JM, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. J Clin Oncol 2010, 28(Suppl):15s. [abstract 4104].
109. Perren A, Komminoth P, Saremaslani P, et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 2000, 157:1097-1103.
110. Karhoff D, Sauer S, Schrader J, et al. Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology 2007, 85:45-53.
111. Shida T, Kishimoto T, Furuya M, et al. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chem Pharmacol 2010, 65:889-893.
112. Catena L, Carbone A, Milione M, et al. mTOR expression in gastrointestinal (GI) tract poorly differentiated endocrine carcinoma (PDEC). ESMO/ECCO 2009, Abstr. p-1323.